



Kelly D. Reihl*, Douglas R. Seals⁺, Grant D. Henson^{*}⁺, Thomas LaRocca⁺, Katherine Magerko⁺, Gary Bosshardt*, Lisa Lesniewski*+, Anthony Donato*+

*Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132 #University of Colorado at Boulder, Boulder, CO 80309

ABSTRACT

Dietary rapamycin inhibits mTOR, reduces age-related pathologies and extends lifespan, but it is unknown if it reverses age-related arterial dysfunction. The effects of mTOR inhibition on endothelial function and arterial stiffness were evaluated in young (Y: 6±2 mo) and old (O: 30±2 mo) male B6D2F1 mice fed control (C) or rapamycin-supplemented diet (RAP: 14mg/kg encapsulated chow) ad libitum for 6 weeks. Aortic mTOR signaling, assessed by S6 Kinase (S6K) Western blot, was higher in aged mice (P<0.05) and lower in rapamycin-treated old mice (P<0.05). Rapamycin selectively increased NO bioavailability (OC v. ORAP, P<0.05) and augmented endotheliumdependent dilation (EDD) to acetylcholine (YC: 96±2%) v. OC: 73± 4%, P<0.05; v. ORAP: 95±1%, P<0.05) in carotid arteries of old mice. RAP also reduced aortic stiffness, assessed by pulse wave velocity, in old animals (Post-Pre: -43±19 cm/s, P<0.05). These improvements coincided with lower aortic nitrotryosine (YC: 1.0±0.2 v. OC: 4.7 ±1.6, P<0.05; v ORAP: 1.5±0.3, P<0.05) and collagen expression (YC: 37±9%) v. OC: 78±5%, P<0.05; v. ORAP: 50±9%, P<0.05). In young mice, RAP impaired endothelial function (P<0.05) and did not affect arterial stiffness. In conclusion, rapamycin improves arterial function in old mice with enhanced mTOR activity, suggesting that mTOR may be an effective therapeutic target in older adults.


BACKGROUND


- Advancing age is one of the major risk factors for developing cardiovascular disease (CVD) and is associated with endothelial dysfunction and arterial stiffening in men and women in the absence of clinical disease²⁻⁶.
- We have previously demonstrated the mammalian target of rapamycin (mTOR) signaling is elevated in arteries from old mice and is associated with endothelial dysfunction and arterial stiffening
- Rapamycin given to aged mice slows multiple signs of aging and extends lifespan⁹.
- Currently, it is unknown if rapamycin treatment and mTOR inhibition can reverse vascular aging.

HYPOTHESIS

We hypothesize that inhibition of mTOR signaling with dietary rapamycin will significantly reverse age-associated arterial stiffening and endothelial dysfunction.

Dietary rapamycin selectively improves arterial function in old mice





the state party party party party party party party party and the party

55 kD



Young

Wilkinson, John E. et al. Rapamycin slows aging in mice. Aging Cell 11, 675-682 (2012). Ramos, FJ., et al. Rapamycin Reverses Elevated mTORC1 Signaling in Lamin A/C-Deficient Mice, Rescues Cardiac and Skeletal Muscle Function, and Extends Survival. Sci Transl Med 144 (25 July 2012). Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395 (2009). 10. Reddy, A. K. et al. Measurement of aortic input impedance in mice: effects of age on aortic stiffness. Am J Physiol Heart Circ Physiol H1464-1470 (2003) 11. Lesniewski, L. A. et al. B6D2F1 Mice are a suitable model of oxidative stress-mediated impaired endothelium-dependent dilation with aging. J Gerontol A Biol Sci Med Sci 64, 9-20 (2009).



Geriatric Research, Education, and Clinical

Center

METHODS

• Mice were purchased from aged rodent colonies maintained at Charles River Inc., and studied at 4-6 mo (young: Y) and 29-31 mo (old: O) of age. • Animals were assigned to one of four experimental groups: young control,

young rapamycin-treated, old control, and old rapamycin-treated. • The mice were housed with a 12:12 light-dark cycle, fed standard chow or standard chow supplemented with rapamycin and water ad libitum for six

weeks (Rapamycin dose at 14 mg/kg of standard chow⁹). Body weight and food/water consumption were monitored weekly before, during, and after 6 weeks of treatment

· Non-terminal measures were performed pre- and post-rapamycin.

Aortic Pulse Wave Velocity

• Aortic pulse wave velocity (PWV) was measured on anesthetized mice before and after treatments by the use of two Doppler probes, one placed externally next to the aortic arch and the other next to the abdominal aorta.

 Distance between the two probes divided by the time required for a bolus of blood to travel from one probe to the other were used to compute the velocity of the pulse. Stiffening of the aorta reduces compliance, thus increasing the speed of the pulse wave.¹⁰

Endothelium In-/Dependent Dilation

 Carotid arteries were incubated in warm physiological saline solution at 37°C, pressurized to 50 mmHg, and allowed to equilibrate for 60 minutes. Vessels were pre-constricted with phenylephrine $(2\mu M)$.

• Lumen diameter was measured in response to cumulative addition of acetylcholine (ACh: 10⁻⁹-10⁻⁴ M), in the absence or presence of the nitric oxide synthase inhibitor, L-NAME (0.1mM).

• ACh responses were repeated in the contra-lateral vessel after incubation with the superoxide dismutase mimetic, TEMPOL (1mM).

• Endothelium-independent dilation (EID) was determined in response to cumulative addition of sodium nitroprusside (SNP: 10⁻⁹-10⁻⁴ M).

• Western blots for nitrotyrosine, a marker of oxidative stress, were performed on aortic lysates

Old RAP

 Aortic tissue was preserved in OCT compound, then cut into 10µm sections. • Histochemistry was performed on aortic sections with picrosirius red, which stains for collagen I and collagen III.

Statistics: Differences in dose responses were determined via Repeated Measures ANOVA and Mean Arterial Pressure/Pulse Wave Velocity via Student's T-test. P≤0.05, with a Bonferonni correction for multiple comparison, P<0.013.

CONCLUSIONS

• Reducing mTOR signaling via six weeks of dietary rapamycin supplementation improved endothelial function and NO bioavailability by lowering oxidative stress in old mice

 Rapamycin treatment in old mice resulted in blunted aortic arterial stiffness and was associated with lower collagen content

 Rapamycin treatment blunted arterial vasoreactivity in young mice suggesting that improvements in arterial function may be limited to arteries with augmented mTOR signalling

1. Kochanek, K. D., Xu, J., Murphy, S. L., Miniño, A. M., Kung, H. C. Deaths: Preliminary Data for 2009. Centers for Disease Control and Prevention National Vital Statistics Report 59, 5 (16 March 2011 Lakatta, E. G. Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises: Part III: Cellular and Molecular Clues to Heart and Arterial Aging. Circulation 107, 490-497 (2003). 3. Eskurza, I., *et al.*. Effect of acute and chronic ascorbic acid augmentation on flow-mediated dilation with physically active and sedentary aging. J Physiol 215-224. (2004) 4. Donato, A. J. et al. Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endotheliumlependent dilation and upregulation of nuclear factor-kappaB. Circ Res 100, 1659-1666 (2007). Gerhard, M., et al. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans

Hypertension 849-853 (1996). Moncada, S., Palmer, R. M. & Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43, 109-